News
FDA Will Ask Sarepta to Halt Gene Therapy Shipments
Digest more
Sarepta Therapeutics lays off 493 workers amid FDA probe, stock drop, and concerns over its gene therapy treatment, Elevidys.
The FDA will request Sarepta Therapeutics stop all shipments of Elevidys, its gene therapy for Duchenne muscular dystrophy, ...
The drop comes the day after the drugmaker said it would add a so-called black-box warning to its gene therapy Elevidys after ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback